| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rectal Neoplasms | 27 | 2024 | 1240 | 4.120 |
Why?
|
| Robotic Surgical Procedures | 10 | 2024 | 533 | 1.740 |
Why?
|
| Colorectal Neoplasms | 14 | 2024 | 3707 | 1.140 |
Why?
|
| Surgical Oncology | 6 | 2020 | 211 | 1.140 |
Why?
|
| Lymph Node Excision | 12 | 2024 | 2062 | 1.040 |
Why?
|
| Laparoscopy | 7 | 2020 | 1302 | 0.990 |
Why?
|
| Education, Medical, Graduate | 6 | 2022 | 705 | 0.900 |
Why?
|
| Gastrointestinal Stromal Tumors | 3 | 2018 | 318 | 0.820 |
Why?
|
| Medicine | 1 | 2023 | 136 | 0.760 |
Why?
|
| Pelvis | 4 | 2024 | 381 | 0.720 |
Why?
|
| Transanal Endoscopic Surgery | 1 | 2020 | 3 | 0.710 |
Why?
|
| Neoadjuvant Therapy | 15 | 2023 | 5231 | 0.710 |
Why?
|
| Surgeons | 2 | 2021 | 491 | 0.600 |
Why?
|
| Clinical Competence | 4 | 2022 | 1325 | 0.590 |
Why?
|
| Colonic Neoplasms | 6 | 2021 | 1435 | 0.590 |
Why?
|
| Ileostomy | 1 | 2018 | 47 | 0.590 |
Why?
|
| Neoplasm Recurrence, Local | 16 | 2024 | 10400 | 0.530 |
Why?
|
| Internship and Residency | 7 | 2022 | 1452 | 0.530 |
Why?
|
| Adrenocortical Carcinoma | 2 | 2014 | 191 | 0.480 |
Why?
|
| Lymph Nodes | 11 | 2024 | 3077 | 0.470 |
Why?
|
| Adrenal Cortex Neoplasms | 2 | 2014 | 242 | 0.470 |
Why?
|
| Patient Care Team | 3 | 2023 | 823 | 0.460 |
Why?
|
| Neoplasm Staging | 15 | 2024 | 14012 | 0.410 |
Why?
|
| NF-kappa B | 2 | 2009 | 1563 | 0.400 |
Why?
|
| Fellowships and Scholarships | 3 | 2021 | 411 | 0.390 |
Why?
|
| Doxorubicin | 2 | 2009 | 3145 | 0.390 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2018 | 625 | 0.380 |
Why?
|
| I-kappa B Kinase | 2 | 2009 | 248 | 0.360 |
Why?
|
| Humans | 71 | 2024 | 270740 | 0.340 |
Why?
|
| Lymphatic Metastasis | 9 | 2024 | 4963 | 0.340 |
Why?
|
| Telemedicine | 4 | 2022 | 552 | 0.320 |
Why?
|
| Adenocarcinoma | 8 | 2023 | 7914 | 0.310 |
Why?
|
| Videoconferencing | 3 | 2018 | 52 | 0.310 |
Why?
|
| Colectomy | 3 | 2019 | 292 | 0.310 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2022 | 7895 | 0.300 |
Why?
|
| Retrospective Studies | 29 | 2024 | 39890 | 0.300 |
Why?
|
| Middle Aged | 35 | 2024 | 90352 | 0.270 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 1838 | 0.270 |
Why?
|
| Curriculum | 3 | 2021 | 919 | 0.270 |
Why?
|
| Anus Neoplasms | 2 | 2022 | 414 | 0.260 |
Why?
|
| Re-Irradiation | 2 | 2018 | 166 | 0.260 |
Why?
|
| Aged | 28 | 2024 | 73333 | 0.250 |
Why?
|
| Chemoradiotherapy | 5 | 2022 | 2027 | 0.240 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2018 | 4961 | 0.240 |
Why?
|
| Adult | 26 | 2024 | 82040 | 0.240 |
Why?
|
| Male | 36 | 2024 | 128315 | 0.240 |
Why?
|
| Melanoma | 2 | 2021 | 5595 | 0.230 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 4895 | 0.230 |
Why?
|
| Female | 38 | 2024 | 148940 | 0.230 |
Why?
|
| Medical Oncology | 2 | 2023 | 1465 | 0.230 |
Why?
|
| Learning Curve | 1 | 2024 | 78 | 0.230 |
Why?
|
| Young Adult | 13 | 2021 | 22251 | 0.220 |
Why?
|
| Length of Stay | 3 | 2024 | 2007 | 0.220 |
Why?
|
| Follow-Up Studies | 12 | 2024 | 15218 | 0.220 |
Why?
|
| Prognosis | 14 | 2024 | 22505 | 0.210 |
Why?
|
| General Surgery | 2 | 2016 | 333 | 0.210 |
Why?
|
| Adrenalectomy | 2 | 2014 | 195 | 0.210 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 625 | 0.210 |
Why?
|
| Patient Selection | 2 | 2020 | 2025 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 5 | 2019 | 4048 | 0.200 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 700 | 0.200 |
Why?
|
| Survival Rate | 11 | 2024 | 12541 | 0.200 |
Why?
|
| Feasibility Studies | 5 | 2024 | 2353 | 0.200 |
Why?
|
| SEER Program | 2 | 2024 | 1047 | 0.200 |
Why?
|
| Ligation | 2 | 2019 | 206 | 0.200 |
Why?
|
| Patient Care Planning | 1 | 2023 | 303 | 0.190 |
Why?
|
| Patient Readmission | 2 | 2024 | 572 | 0.190 |
Why?
|
| Incisional Hernia | 1 | 2021 | 15 | 0.190 |
Why?
|
| Metastasectomy | 1 | 2023 | 209 | 0.190 |
Why?
|
| Postoperative Complications | 5 | 2024 | 5681 | 0.180 |
Why?
|
| Abdominal Wound Closure Techniques | 1 | 2021 | 43 | 0.180 |
Why?
|
| Aged, 80 and over | 11 | 2024 | 30998 | 0.180 |
Why?
|
| Mesocolon | 1 | 2019 | 8 | 0.170 |
Why?
|
| Social Class | 1 | 2021 | 324 | 0.170 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2020 | 442 | 0.170 |
Why?
|
| Personnel Selection | 1 | 2020 | 89 | 0.160 |
Why?
|
| Pelvic Floor | 1 | 2019 | 44 | 0.160 |
Why?
|
| DNA Mismatch Repair | 2 | 2023 | 283 | 0.160 |
Why?
|
| Fertility Preservation | 1 | 2021 | 151 | 0.160 |
Why?
|
| Eligibility Determination | 1 | 2019 | 85 | 0.160 |
Why?
|
| Hernia, Ventral | 1 | 2021 | 163 | 0.160 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2020 | 275 | 0.160 |
Why?
|
| Interviews as Topic | 1 | 2020 | 521 | 0.160 |
Why?
|
| Abdominal Wall | 1 | 2021 | 193 | 0.150 |
Why?
|
| Transcription Factor RelA | 2 | 2009 | 184 | 0.150 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 4130 | 0.150 |
Why?
|
| Self Concept | 1 | 2019 | 198 | 0.150 |
Why?
|
| Disease-Free Survival | 7 | 2024 | 10265 | 0.150 |
Why?
|
| Needs Assessment | 1 | 2019 | 238 | 0.150 |
Why?
|
| Suture Techniques | 2 | 2021 | 292 | 0.150 |
Why?
|
| Genetic Testing | 3 | 2022 | 1696 | 0.150 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2016 | 1828 | 0.150 |
Why?
|
| Texas | 5 | 2020 | 6449 | 0.150 |
Why?
|
| Mesenteric Artery, Inferior | 1 | 2017 | 5 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2021 | 2828 | 0.140 |
Why?
|
| Liver Neoplasms | 3 | 2024 | 4821 | 0.140 |
Why?
|
| Cytoskeletal Proteins | 2 | 2010 | 522 | 0.140 |
Why?
|
| Prospective Studies | 7 | 2022 | 13414 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2023 | 1097 | 0.140 |
Why?
|
| Pelvic Neoplasms | 1 | 2018 | 199 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 533 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2022 | 16689 | 0.130 |
Why?
|
| Patient Satisfaction | 2 | 2019 | 917 | 0.130 |
Why?
|
| Treatment Outcome | 12 | 2024 | 33737 | 0.130 |
Why?
|
| Patient Handoff | 1 | 2016 | 41 | 0.130 |
Why?
|
| Apoptosis | 2 | 2013 | 7757 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 681 | 0.130 |
Why?
|
| Confidence Intervals | 2 | 2015 | 749 | 0.130 |
Why?
|
| Postoperative Care | 2 | 2017 | 728 | 0.130 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 359 | 0.130 |
Why?
|
| Colon | 1 | 2019 | 659 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2013 | 5408 | 0.130 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 743 | 0.120 |
Why?
|
| Recovery of Function | 1 | 2019 | 681 | 0.120 |
Why?
|
| Robotics | 1 | 2019 | 365 | 0.120 |
Why?
|
| RNA, Small Interfering | 3 | 2013 | 2196 | 0.120 |
Why?
|
| United States | 7 | 2024 | 15861 | 0.120 |
Why?
|
| Role | 1 | 2014 | 45 | 0.120 |
Why?
|
| Neoplasms | 4 | 2022 | 15927 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2022 | 5593 | 0.120 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2017 | 509 | 0.120 |
Why?
|
| Phosphoproteins | 2 | 2010 | 1138 | 0.110 |
Why?
|
| Communication | 2 | 2017 | 839 | 0.110 |
Why?
|
| Neuroendocrine Tumors | 2 | 2020 | 656 | 0.110 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 662 | 0.110 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2023 | 1903 | 0.100 |
Why?
|
| Preoperative Care | 2 | 2018 | 1567 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 984 | 0.100 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 12033 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2015 | 318 | 0.100 |
Why?
|
| Pancreatectomy | 1 | 2016 | 696 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 3 | 2016 | 5257 | 0.090 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 354 | 0.090 |
Why?
|
| Adolescent | 6 | 2021 | 32767 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 5923 | 0.090 |
Why?
|
| Survival Analysis | 4 | 2018 | 9292 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2022 | 2178 | 0.090 |
Why?
|
| Rectum | 2 | 2023 | 480 | 0.090 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2013 | 296 | 0.090 |
Why?
|
| Cohort Studies | 4 | 2018 | 9470 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 1379 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 2400 | 0.090 |
Why?
|
| NF-kappa B p52 Subunit | 1 | 2009 | 26 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 596 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2016 | 850 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2017 | 2123 | 0.080 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2013 | 809 | 0.080 |
Why?
|
| Obesity | 1 | 2020 | 2904 | 0.080 |
Why?
|
| Imatinib Mesylate | 1 | 2012 | 1691 | 0.080 |
Why?
|
| Deoxycytidine | 1 | 2013 | 1389 | 0.070 |
Why?
|
| Pandemics | 3 | 2022 | 1610 | 0.070 |
Why?
|
| Sarcoma | 2 | 2020 | 1839 | 0.070 |
Why?
|
| Cytoskeleton | 1 | 2008 | 295 | 0.070 |
Why?
|
| Cell Line, Tumor | 4 | 2013 | 14849 | 0.070 |
Why?
|
| Benchmarking | 2 | 2021 | 275 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 1347 | 0.070 |
Why?
|
| Benzamides | 1 | 2012 | 1879 | 0.070 |
Why?
|
| Hepatectomy | 2 | 2024 | 1015 | 0.070 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2023 | 1402 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 3597 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2009 | 742 | 0.070 |
Why?
|
| Extracellular Matrix | 1 | 2008 | 524 | 0.060 |
Why?
|
| Radiotherapy | 1 | 2013 | 1857 | 0.060 |
Why?
|
| Cell Death | 1 | 2008 | 685 | 0.060 |
Why?
|
| Betacoronavirus | 2 | 2020 | 514 | 0.060 |
Why?
|
| Quality of Life | 1 | 2019 | 4761 | 0.060 |
Why?
|
| Fluorouracil | 2 | 2022 | 1990 | 0.060 |
Why?
|
| Databases, Factual | 3 | 2019 | 2250 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2013 | 4942 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2024 | 6256 | 0.060 |
Why?
|
| Time Factors | 2 | 2017 | 13006 | 0.060 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2017 | 562 | 0.060 |
Why?
|
| Seminal Vesicles | 1 | 2024 | 149 | 0.060 |
Why?
|
| Viscera | 1 | 2024 | 92 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 2617 | 0.060 |
Why?
|
| Anastomotic Leak | 1 | 2024 | 83 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 7783 | 0.060 |
Why?
|
| Piperazines | 1 | 2012 | 2145 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2024 | 6764 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2008 | 1474 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 7655 | 0.050 |
Why?
|
| Transfection | 1 | 2008 | 3117 | 0.050 |
Why?
|
| Subcutaneous Tissue | 1 | 2003 | 57 | 0.050 |
Why?
|
| Elective Surgical Procedures | 1 | 2024 | 249 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2008 | 1958 | 0.050 |
Why?
|
| Europe | 1 | 2024 | 658 | 0.050 |
Why?
|
| Accidents, Traffic | 1 | 2003 | 118 | 0.050 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 1101 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2023 | 9039 | 0.050 |
Why?
|
| Abdominal Injuries | 1 | 2003 | 122 | 0.050 |
Why?
|
| Operative Time | 1 | 2023 | 255 | 0.050 |
Why?
|
| Accreditation | 1 | 2022 | 137 | 0.050 |
Why?
|
| Protein Binding | 1 | 2008 | 3485 | 0.050 |
Why?
|
| Netherlands | 1 | 2021 | 90 | 0.050 |
Why?
|
| Patient Discharge | 2 | 2017 | 698 | 0.050 |
Why?
|
| Microsatellite Instability | 1 | 2023 | 408 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 3339 | 0.050 |
Why?
|
| Mitomycin | 1 | 2022 | 213 | 0.050 |
Why?
|
| Cell Movement | 1 | 2008 | 2472 | 0.050 |
Why?
|
| Problem-Based Learning | 1 | 2021 | 79 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 1248 | 0.050 |
Why?
|
| Australia | 1 | 2021 | 259 | 0.050 |
Why?
|
| Endoscopy | 1 | 2023 | 496 | 0.040 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2020 | 43 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2024 | 5101 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2012 | 3669 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2022 | 417 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 2020 | 79 | 0.040 |
Why?
|
| Documentation | 1 | 2021 | 213 | 0.040 |
Why?
|
| Mesenteric Arteries | 1 | 2019 | 64 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 2019 | 80 | 0.040 |
Why?
|
| Perception | 1 | 2021 | 349 | 0.040 |
Why?
|
| Mesenteric Veins | 1 | 2019 | 83 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2020 | 315 | 0.040 |
Why?
|
| Fertility | 1 | 2021 | 336 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2021 | 4000 | 0.040 |
Why?
|
| Shock, Hemorrhagic | 1 | 1999 | 79 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2003 | 715 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2021 | 397 | 0.040 |
Why?
|
| Pneumonectomy | 1 | 2023 | 862 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 5149 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2019 | 282 | 0.040 |
Why?
|
| Logistic Models | 1 | 2024 | 3444 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 14617 | 0.030 |
Why?
|
| Inpatients | 1 | 2022 | 683 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2014 | 2271 | 0.030 |
Why?
|
| Incidence | 2 | 2018 | 5824 | 0.030 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2017 | 103 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2021 | 1060 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2019 | 1075 | 0.030 |
Why?
|
| Biopsy | 1 | 2023 | 3484 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2018 | 293 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 279 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2010 | 6390 | 0.030 |
Why?
|
| Decision Making | 1 | 2022 | 1252 | 0.030 |
Why?
|
| Cisplatin | 1 | 2022 | 2497 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2015 | 413 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 1999 | 1050 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 5776 | 0.030 |
Why?
|
| bcl-Associated Death Protein | 1 | 2013 | 24 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 497 | 0.030 |
Why?
|
| Mice | 3 | 2010 | 35600 | 0.030 |
Why?
|
| Peritoneal Neoplasms | 1 | 2020 | 859 | 0.030 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2014 | 180 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 727 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2013 | 251 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2014 | 283 | 0.030 |
Why?
|
| Trans-Activators | 1 | 1999 | 1624 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 3298 | 0.020 |
Why?
|
| Risk Factors | 2 | 2023 | 17888 | 0.020 |
Why?
|
| Electrons | 1 | 2013 | 188 | 0.020 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2016 | 706 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2017 | 2580 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2019 | 1207 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2020 | 6224 | 0.020 |
Why?
|
| Animals | 4 | 2010 | 61956 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 16215 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 1076 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 1939 | 0.020 |
Why?
|
| Pyridazines | 1 | 2013 | 324 | 0.020 |
Why?
|
| Research Design | 1 | 2017 | 1569 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2013 | 1356 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 1823 | 0.020 |
Why?
|
| Age Factors | 1 | 2019 | 5457 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 2311 | 0.020 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 587 | 0.020 |
Why?
|
| Immunoassay | 1 | 2010 | 214 | 0.020 |
Why?
|
| Liver | 1 | 1999 | 3086 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 2835 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2010 | 848 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2014 | 914 | 0.020 |
Why?
|
| Imidazoles | 1 | 2013 | 1065 | 0.020 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2008 | 236 | 0.020 |
Why?
|
| Disease Progression | 1 | 2018 | 6867 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 4960 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2008 | 1028 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 1999 | 5002 | 0.020 |
Why?
|
| Actins | 1 | 2008 | 602 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 3640 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 6177 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2013 | 4019 | 0.020 |
Why?
|
| Biomarkers, Tumor | 2 | 2016 | 10708 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2010 | 2422 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2010 | 1654 | 0.010 |
Why?
|
| Abbreviated Injury Scale | 1 | 2003 | 10 | 0.010 |
Why?
|
| Skinfold Thickness | 1 | 2003 | 34 | 0.010 |
Why?
|
| Injury Severity Score | 1 | 2003 | 246 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2013 | 7238 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 3345 | 0.010 |
Why?
|
| Reference Values | 1 | 1999 | 1133 | 0.010 |
Why?
|
| Resuscitation | 1 | 1999 | 274 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2003 | 2232 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1999 | 2315 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1999 | 2156 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1999 | 3476 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 1999 | 1136 | 0.010 |
Why?
|
| Mutation | 1 | 2010 | 15912 | 0.010 |
Why?
|
| Rats | 1 | 1999 | 6441 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1999 | 7381 | 0.000 |
Why?
|